Form 4 for BCRX BIOCRYST PHARMACEUTICALS INC
Accepted 2023-03-23 00:00:00 ET · period of report 2023-03-21 · accession 0001127602-23-011193 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-23 | 2023-03-21 | BCRX | Stonehouse Jon P | Pres, CEO, Dir | M - OptEx | $3.22 | +31.1K | 1.04M | +3% | +$100.0K |
| D | 2023-03-23 | 2023-03-21 | BCRX | Stonehouse Jon P | Pres, CEO, Dir | M - OptEx | $0.00 | -31.1K | 306.0K | -9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-21 | M | A | 31,055 | $3.22 | 1,039,794 | D | — | — | |
| 2 | Derivative | Emp. Stock Option (Right to Buy) | 2023-03-21 | M | D | 31,055 | $0.00 | 305,995 | D | $3.22 · 2017-05-23 to 2026-05-23 | 31,055 Common Stock |